Comprehensive outcomes of on‐ and off‐antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis
- Authors
- An, Ji hyun; Shim, Ju Hyun; Kim, Seon-Ok; Choi, Jonggi; Kim, Sang-We; Lee, Danbi; Kim, Kang Mo; Lim, Young-Suk; Lee, Han Chu; Chung, Young-Hwa; Lee, Yung Sang; Suh, Dong Jin
- Issue Date
- Sep-2016
- Publisher
- WILEY-BLACKWELL
- Keywords
- hepatitis B virus; chemotherapy; antiviral prophylaxis; cancer; relapse; reactivation
- Citation
- JOURNAL OF MEDICAL VIROLOGY, v.88, no.9, pp.1576 - 1586
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF MEDICAL VIROLOGY
- Volume
- 88
- Number
- 9
- Start Page
- 1576
- End Page
- 1586
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4952
- DOI
- 10.1002/jmv.24512
- ISSN
- 0146-6615
- Abstract
- Although antiviral prophylaxis is essential in hepatitis B patients in the context of cancer chemotherapy, there is little evidence-based consensus regarding the appropriate prevention strategy depending on the underlying type of cancer and viral status. This retrospective study included a comprehensive cohort of 302 hepatitis B surface antigen-positive patients with various cancers undergoing chemotherapy and antiviral prophylaxis. The rates of hepatitis B virus (HBV) reactivation during antiviral therapy (>1 log10 IU/mL increase or positive conversion of serum HBV DNA) and relapse when off antivirals ([re]appearance of HBV DNA >2,000 IU/ml with related alanine aminotransferase elevation) were evaluated, together with the associated risk factors, in a competing risks analysis where cancer death was considered as the competing event. During antiviral prophylaxis, HBV was reactivated in six patients (1.9%), who had leukemia (n = 4) or lymphoma (n = 2) and were treated with lamivudine (n = 4) or entecavir (n = 2). The incidence rate of HBV relapse in 127 off-prophylaxis patients was 21.3% during a median post-antiviral period of 11.7 months. Lymphoma, pre-prophylactic HBV DNA ≥2,000 IU/ml, and age ≥50 years were independent predictors of off-treatment HBV relapse (adjusted hazard ratios 5.25, 3.07, and 0.34, respectively; Ps < 0.05). Antiviral and anticancer drugs, duration of consolidation on antiviral prophylaxis, and HBeAg positivity were not independent predictors. In conclusion, hepatitis B flare-ups are not rare in patients receiving cancer chemotherapy during and after anti-HBV prophylaxis, even when potent antivirals are used. Patients with hematopoietic or lymphoid neoplasms or high viral burdens should receive prolonged and powerful HBV prophylaxis. J. Med. Virol. 88:1576-1586, 2016.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4952)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.